GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (SHSE:688366) » Definitions » Equity-to-Asset

Shanghai Haohai Biological Technology Co (SHSE:688366) Equity-to-Asset : 0.80 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shanghai Haohai Biological Technology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥5,755 Mil. Shanghai Haohai Biological Technology Co's Total Assets for the quarter that ended in Mar. 2024 was ¥7,193 Mil. Therefore, Shanghai Haohai Biological Technology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.80.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's Equity-to-Asset or its related term are showing as below:

SHSE:688366' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.78   Med: 0.81   Max: 0.95
Current: 0.8

During the past 10 years, the highest Equity to Asset Ratio of Shanghai Haohai Biological Technology Co was 0.95. The lowest was 0.78. And the median was 0.81.

SHSE:688366's Equity-to-Asset is ranked better than
67.82% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs SHSE:688366: 0.80

Shanghai Haohai Biological Technology Co Equity-to-Asset Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Equity-to-Asset Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.87 0.82 0.80 0.80

Shanghai Haohai Biological Technology Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.79 0.81 0.80 0.80

Competitive Comparison of Shanghai Haohai Biological Technology Co's Equity-to-Asset

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Equity-to-Asset falls into.



Shanghai Haohai Biological Technology Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Shanghai Haohai Biological Technology Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=5650.064/7105.497
=0.80

Shanghai Haohai Biological Technology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=5755.069/7192.953
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co  (SHSE:688366) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Shanghai Haohai Biological Technology Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co (SHSE:688366) Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co (SHSE:688366) Headlines

No Headlines